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Advisory Professor: Don L. Gibbons, M.D., Ph.D.
The microRNA-200 family is known to be a master regulator of the epithelialto-mesenchymal transition, partially through its double-negative feedback loop with
the transcriptional repressor Zeb1, yet the mechanisms on how miR-200 controls the
invasive phenotype are not fully understood. Recent studies have shown that the
miR-200/Zeb1 axis regulates cell-cell and cell-matrix interactions, but it has also
been demonstrated that cell-intrinsic changes are insufficient to drive cancer cell
invasion, leading us to focus on specific cell-matrix interactions required to activate
tumor cell invasion and metastases. We have shown through 3D studies that the
Integrin β1-collagen I contact is critical in mediating the invasive phenotype in cells
with miR-200 loss or Zeb1 overexpression. Furthermore, those genetic changes
enhanced the cells responsiveness to the ECM through the FAK/Src pathway. The
importance of this pathway in our Kras and p53 mouse model and in human lung
cancer cell lines was further studied using pharmacological inhibitors and an shRNAbased knockdown approach, which exhibited a significant suppression of migration
and invasion in Boyden chambers and 3D invasion assays. Furthermore,
pharmacological inhibition of Src prevented distant metastases in vivo. We found
vi

that miR-200 regulates the activation of the FAK/Src pathway through direct
targeting of CRKL, an integrin adaptor molecule. Our studies suggest that CRKL is
critical in enhancing the outside-in signaling through Itgβ1 but also involved in the
inside-out signaling by maintaining the cell-matrix contact required for continuous
cell invasion. Those findings highlight the importance of the ECM composition, in
addition to cell-intrinsic changes, that regulate the activation of intracellular signaling
pathways required for tumor cell invasion and metastases that allow for targeting at
multiple levels.
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Chapter 1
Introduction

1

Lung cancer
Lung cancer is a heterogeneous disease that is divided into two main types,
non-small cell lung cancer (NSCLC, ~ 80-85 %) and small cell lung cancer (~15-20
%). NSCLC can be further classified into adenocarcinoma, squamous carcinoma,
large cell carcinoma, bronchoalveolar lung cancer and mixed types [1]. Lung cancer
is listed as the second cancer type in the number of new estimated cases in both
men and women and the leading cause of all cancer-related deaths, accounting for
160,000 deaths per year in the United States. This can be explained by the fact that
almost 2/3 of the patients when they first present already have metastatic disease,
which has a 5 year survival rate of less than 5 % and has not changed over the past
decades [2]. Understanding the molecular mechanisms underlying metastasis is
therefore crucial in developing better treatment strategies. In order to study
metastasis, a mouse model was previously developed in which mice carrying a
somatic activation of the KrasG12D allele will develop lung adenocarcinoma but not
metastasize. Introduction of the mutant p53 allele (p53R172HΔG), commonly found in
Li-Fraumeni syndrome, into those mice causes the development of atypical
adenomatous

hyperplasia,

adenomas

and

adenocarcinomas.

The

lung

adenocarcinomas found in this model are highly metastatic, with metastases found
at sites commonly seen in NSCLC patients. Transcriptional profiling of the tumors
derived from this mouse model revealed a metastases signature that correlated with
a subset of NSCLC patients with poor prognosis [3, 4].
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Metastases and epithelial-to-mesenchymal transition
Metastasis is a complex, multi-step process, in which cancer cells
disseminate from the primary tumor by invasion into the surrounding ECM,
intravasate, are transported through the blood circulation and extravasate from the
blood vessels at distant organs, where they can form secondary tumors through
establishment of micro-metastases, allowing for a rapid spread of cancer cells [5]. It
is thought that cancer cells typically undergo an epithelial-to-mesenchymal transition
(EMT) in order to gain migratory and invasive properties. Epithelial cells, found in the
primary tumor, are characterized by tight junctions and an apical-basal polarity, and
their cobble-stone like organization. Mesenchymal cells show an increased
expression of mesenchymal markers, such as N-cadherin, ZEB1/2 and vimentin,
allowing for increased motility through a decrease in cell-cell contact, displayed by
their scattered, fibroblast-like appearance [6-8]. The transcriptional repressors ZEB1
and ZEB2 have been shown to regulate EMT by suppressing the transcription of
epithelial markers such as E-cadherin by binding to the E-boxes in the promoter
region [9]. Furthermore, the invasive phenotype that tumor cells acquire upon
metastasis is characterized by a reorganization of the actin cytoskeleton to drive the
leading edge of the cell forward and to recruit actin-associated proteins and metalloproteases necessary for the degradation of the extracellular matrix (ECM).
miR-200/ZEB1 axis and the extracellular matrix
MicroRNAs are small non-coding RNAs that bind to the 3’ untranslated region
(3’UTR) of genes, thereby regulating their expression by targeting them for
degradation or repression of translation [10]. The miR-200 family consists of five
3

family members, 200a/b/c, 141 and 429, located on two different genomic loci: 200b200a-429 (chromosome 1) and 141-200c (chromosome 12). MiR-200 has been
shown to be a master regulator of EMT, partially through the double-negative
feedback loop with the transcriptional repressors ZEB1/2, maintaining the epithelial
phenotype [11-15]. Previous studies have shown that loss of miR-200 is necessary
and sufficient to drive EMT [16], yet the detailed mechanism on how the
mesenchymal phenotype is maintained are not fully understood.
Recent studies have been focused on the importance of the ECM in
mediating tumor cell activation, indicating that metastasis is driven by a combination
of cell-intrinsic and cell-extrinsic changes. The miR-200/ZEB1 axis is known to
regulate both, cell-intrinsic and cell-extrinsic changes, by modulating EMT markers
and specific ECM components. Over the past years studies have shown that the
ECM undergoes dramatic changes during tumor progression, affecting the tension in
the surrounding microenvironment (e.g. through collagen fibers) as well as
differential expression patterns of microRNAs and integrins, which further alter
downstream signaling pathways [7, 17, 18]. Proteomic profiling of cell lines derived
from our murine model showed differential expression of cell adhesion and ECM
proteins in metastatic vs. non-metastatic cell lines [19].
Tumor cell-ECM interactions through integrins
The interaction of cells with the ECM is mainly mediated through integrins,
heterodimeric receptors leading to the activation of downstream intracellular
signaling pathways. There are 18 α and 8 β subunits whose pairs are unique to their
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ligands. Structurally they are transmembrane glycoproteins with a large N-terminal
extracellular domain, a single transmembrane domain and a short non-catalytic Cterminal intracellular tail. Many of the integrin subunits have been implicated to play
an important role in cancer progression due to their role in migration and invasion in
which they mediate the adhesion to the ECM and as result are able to regulate
various intracellular signaling pathways. It is known that Integrins re-localize to
adhesive structures causing alterations in their binding ability to the ECM. Once they
bind to the ECM, cluster formation of the integrins is initiated, allowing for the
recruitment of adaptor molecules, connecting the integrins with the actin
cytoskeleton, kinases and other transmembrane growth-factor receptors. Integrins
function through a bi-directional signaling: outside-in and inside-out. For the insideout signaling, intracellular ligands (e.g. talins) cause the separation of the
cytoplasmic tails which in turn promotes the binding of ECM ligands to the
extracellular domain. The outside-in signaling is initiated by the binding of ECM
ligands to the N-terminus, causing the separation of the cytoplasmic domains which
allows for the interaction with adaptor molecules. It has been shown that increased
integrin activation is necessary for cancer cell migration and metastases, even
suggesting that cancer cells might use specific integrin-ligand combinations at
distant sites to allow for colonization and to receive mitogenic signals. Integrin
signaling, especially through β1, involves the activation of the focal adhesion kinase
(FAK), leading to further downstream recruitment of adaptor molecules such as
paxillin and p130cas [20, 21]. Blocking antibodies and a non-RGD (Arginyl-glycylaspartic acid ) based peptide inhibitor have been used to inhibit Integrin β1 which
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suppressed in vitro and in vivo growth of human breast cancer and the monoclonal
antibody volociximab against α5β1 has shown good efficacy and tolerance in Phase
I studies. Furthermore, the blocking antibody has been shown to increase apoptosis
in 3D breast cancer models and sensitized cancer cells to irradiation in breast
cancer xenografts [20, 22, 23].
Focal adhesions and FAK/Src signaling
Focal adhesions are considered clusters of transmembrane receptors of
integrin and cytoplasmic proteins such as FAK and other adaptor molecules involved
in downstream signaling [24]. FAK is a signaling kinase and adaptor scaffold protein
with an auto-phosphorylation site at tyrosine 397 [25]. Upon FAK activation, its
substrate Src is recruited, leading to further phosphorylation of the tyrosine residues
576/577, 861 and 925. Multiple studies have shown that activation of FAK promotes
cell survival and motility. Furthermore, many cancers have increased FAK protein
expression, which can lead to the formation of invasive structures such as
podosomes and invadopodia, necessary for metastases [20, 25]. It has been shown
that FAK is phosphorylated and re-localized to sites of focal adhesions in stiffer
matrices, which are found upon the ECM remodeling occurring during tumor
progression [8, 18]. Furthermore, FAK inhibition using siRNA has been
demonstrated to increase cell-cell adhesion, an epithelial characteristic, through Ecadherin modulation and to reduce cell invasion [21].
FAK and many of the adaptor molecules involved in focal adhesion signaling
are known Src substrates. Src is one of the 11 Src-family kinase members, which
contains an auto-phosphorylation site in the activation loop. In addition to the
6

positive regulatory site at residue Y416 (auto-phosphorylation site) it also has a
negative regulatory site at residue Y527. The tyrosine kinase Src is an oncogene
that is overexpressed in many cancer types and known to be involved in multiple
cellular processes, such as proliferation, cell morphology, migration, invasion and
adhesion. It is negatively regulated by the C-terminal Src kinase (CSK) which
phosphorylates Src at residue Y527 to inactivate Src [26]. Furthermore, Src is
regulated by protein tyrosine phosphatases which de-phosphorylate Src at its
negative regulatory site. The tyrosine kinase acts as signal transducer from cell
surface receptors (e.g. integrins) through phosphorylation of tyrosine residues on
substrates such as FAK, Cas and paxillin. Src inhibition has been shown to
decrease migration in vitro, tumor growth and invasion in vivo in NSCLC using
murine xenograft models [27, 28]. Furthermore, inhibition of Src using the ATP
binding competitive inhibitor Dasatinib decreased the development of liver
metastases in a murine model of pancreatic carcinoma and caused a decrease in
cell adhesion, migration and invasion in colon cancer cell lines. In thyroid cancer cell
lines, Dasatinib was shown to have a cytostatic activity both in vitro and in vivo
causing cell cycle arrest and an increase in senescence [29]. Yet, Dasatinib has only
been used on patients with advanced disease and therefore not been proven
successful in clinical trials. In addition to Dasatinib, the more specific Src inhibitor
Saracatinib (AZD0530) has been used in multiple studies resulting in a growth
inhibition in several cancer cell lines and reduced migration and invasion [30].
Combination treatment of Saracatinib with an EGFR/HER2 drug in breast cancer
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has shown to cause cell cycle arrest and as result suppressed the formation of brain
metastases which are normally promoted by Src [31].
The formation of the FAK/Src complex at sites of focal adhesions is
necessary in mediating cell-matrix contacts and cytoskeletal reorganization, mostly
through regulating the phosphorylation status of the cytoskeletal protein cortactin,
which is involved in cell adhesion, migration and invasion [25, 32]. The focal
adhesion complex formation is facilitated by adaptor molecules such as CRKL,
linking the cell-matrix interactions to intracellular signaling activation [33].
CRKL
CRKL, an integrin adaptor molecule, belongs to the family of CRK proteins,
known to control transcription and the cytoskeleton through downstream signaling
cascades. They are activated through extracellular and intracellular stimuli, such as
growth factors, cytokines and the tyrosine kinase Bcr-Abl, respectively. CRKL has
been implicated to play a role in proliferation, adhesion, survival, migration and
invasion [34, 35]. It has been found to be overexpressed in many cancer types,
including lung, breast, skin, ovarian and colon cancer, primarily leading to enhanced
adhesion

to

fibronectin,

an

ECM

protein

[33,

36-38].

Furthermore,

the

phosphorylation status of CRKL is used as a prognostic factor for CML survival [39].
It is known to directly interact with paxillin and p130Cas and translocates to focal
adhesions upon Src activation [40].

8

This study is focused on understanding how the miR-200/ZEB1 axis controls
the matrix-dependent tumor cell activation by modulating cell-cell and cell-matrix
interactions and cytoskeletal changes, necessary to drive the invasive phenotype.

9

Chapter 2
Materials and
Methods

10

Animal studies.
All animal experiments were approved by the institutional animal care and
use committee (IACUC) at the University of Texas M.D. Anderson Cancer Center.
Wild type male and female mice from the 129/sv strain with a minimum age of 2
months were used for the mice experiments. 0.5 -1 x 106 cells were subcutaneously
injected in the flank in a volume of 100 μl in serum free RPMI. The animals received
intraperitoneal injections 5 days a week with dasatinib (purchased from
Selleckchem) at a dose of 10 mg/kg or 20 mg/kg in a volume of 50 μl or the vehicle
DMSO. The animals were monitored for tumor burden and sacrificed once the tumor
size exceeded 15 mm or euthanized due to tumor ulcerations. Mice were examined
for metastasis and tissues for the subcutaneous tumor, lungs and any organs with
visible metastasis were collected. The results are represented as mean ± standard
deviation and student’s t-test was performed for statistical significance.
Cell culture.
Cell lines derived from the mutant Kras and p53 lung adenocarcinoma mouse
model (previously published [16]) and human lung cancer cells H157 were cultured
in RPMI1640 with 10 % fetal bovine serum (FBS) (Table 1). HEK 293T cells were
cultured in DMEM with 10 % fetal bovine serum (FBS).
Cell line
393LN
412P
393P
307P
531P1
531LN2
531LN3

Species
murine
murine
murine
murine
murine
murine
murine
11

344LN
531LN1
344P
344SQ

murine
murine
murine
murine

344SQ_200
393P_vec
393P_ZEB1
393_ZEB1_vec
393P_ZEB1_200

murine
murine
murine
murine
murine

H157
H157 pTRIPZ
H157 200ab

human
human
human

Table 1. Cell lines used in the study

Inhibitors and blocking antibodies.
The inhibitors dasatinib, AZD0530 and imatinib were a kind gift from Dr. Faye
Johnson (MD Anderson). TGF-β was purchased from Cell Signaling (#8915LF). FAK
inhibitor 14 (Y15) was purchased from Santa Cruz (sc-203950). All blocking
antibodies and Ig controls were purchased from BD Biosciences and used at a final
concentration of 8 μg/ml: Itgβ1 (BD 555002), Itgβ3 (BD 553343), IgM (BD 553957),
IgG (553950).
Generation of pLenti6.3 Src dominant active (DA) and dominant negative (DN)
constructs.
Src DA Y527F and Src DN K295R plasmids were purchased from Addgene
(Plasmid 17675 and 17678). Following the Gateway® Technology cloning manual
PCR primers were designed adding attB sites to each of the Src DNA sequences
(Src attB F: GGGGACAACTTTGTACAAAAAAGTTGGCATGGGGAGCAGCAAGA
GC, Src attB R: GGGGACAACTTTGTACAAGAAAGTTGGGCTATAGGTTCTCTCC
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AGG). The obtained PCR products were further cloned into a pDONR221 vector
using a BP reaction (Invitrogen 56481) and the resulting plasmids cloned into the
Destination vector pLenti6.3 EF (kindly provided by Dr. Kenneth Scott, Baylor
College of Medicine) using a LR reaction (Invitrogen 56484). The final plasmids were
confirmed using Sanger sequencing and used for lentiviral infection.
Lentivirus transfection.
Lentiviral-based Itgβ1 shRNA were purchased from Thermo Scientific
(mouse:

TRCN0000066643,

TRCN0000066646,

TRCN0000066644,

TRCN0000066647

(also

targets

TRCN0000066645,
human

Itgβ1),

human:

TRCN0000029645, TRCN0000029648). Lentiviral-based CRKL shRNA were
purchased from Thermo Scientific (mouse: TRCN0000097199, TRCN0000097200,
TRCN0000097202, TRCN0000097203). Murine Csk cDNA was purchased from
Origene (MC203625) and cloned into the pTRIPZ-GFP vector. 293T cells were
seeded one day prior to transfection. 2 μg DNA construct, 1.5 μg psPAX2 (gag-ProPol, for packaging) and 0.5 μg pMD2.G (envelope plasmid) were mixed and added
to Opti-MEM® (GIBCO). PLUS™ reagent (Invitrogen) was added to the mixture and
incubated for 5 minutes at room temperature. After addition of Lipofectamine® LTX
(Invitrogen), the mixture was incubated for 30 minutes at room temperature and
added to the cells. 8-12 hours post-transfection, the transfection mixture was
replaced with fresh DMEM. Virus was collected 3 times every 12 hours after a 24
hour recovery period and stored on ice at 4 °C. The virus was filtered using a 0.45
μm syringe filter and polybrene (8 μg/ml, Millipore) was added for efficient infection
and incubated for 10 minutes at room temperature. The target cells (344SQ,
13

393P_ZEB1 and H157) were infected 2 times with the virus (with an 8 hour time
period in between infections). The virus was replaced with fresh RPMI 12 hours past
the 2nd transfection and after a 24 hour recovery period antibiotic selection was
started.
siRNA transfection.
The human CRKL siRNA SMARTpool was purchased from Dharmacon (L012023-00-0005) and used at a final concentration of 25 nM. One day before
transfection, cells were plated in 6 well plates. The siRNA and DharmaFECT I
(Dharmacon) were separately diluted in serum-free RPMI and incubated for 5
minutes at room temperature. The diluted siRNA was added to the DharmaFECT
mix and incubated for 20 minutes at room temperature before adding it to the cells.
RNA and lysates were collected 48 hours post transfection.
Migration and Invasion Assay.
Cells were seeded at a density of 5 x 104 per well in serum-free media in a
24-well Transwell or Matrigel plate (BD Biosciences, pore size 8 μm). RPMI with
10 % FBS was placed in the lower chamber as a chemoattractant and cells were
allowed to migrate for 6 hours (H157 cells) or 16 hours (murine cells) at 37 °C at 5 %
CO2. The migrated/invaded cells were stained with 0.1 % crystal violet and nonmigrated/invaded cells in the upper chamber removed using a cotton swab. Five
microscopic fields at a 4x magnification were captured from each well and
migrated/invaded cells counted. The results are represented as mean ± standard
deviation and student’s t-test was performed for statistical significance. The graphs
in each figure represent one experiment. Each assay was performed in triplicates.
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Cell Adhesion Assay.
Wells of a 24 well plate were coated with a thin layer of either Fibronectin
(10 μg/ml, Sigma F1141), Matrigel, Matrigel/Collagen type I (final concentration
1.5 mg/ml) or Collagen type I (final concentration 1.5 mg/ml, Corning). Cells were
pre-treated with Y15 (5 μM) for 24 hours before 50,000 cells/well were plated. After
the incubation time, each well was washed twice with PBS to remove unattached
cells, fixed for 10 minutes at room temperature with 10 % formalin, washed with PBS
and stained using 0.1 % Crystal Violet/PBS. Images are representatives of the
triplicates performed for each condition. For the washout experiment, pre-treated
cells were washed and added to the wells without Y15. Quantification of cell
adhesion was measured by the absorbance at 595 nm after dissolving the crystal
violet stained cells in 10 % acetic acid for 20 min.
Quantitative Real-Time PCR.
RNA was isolated using TRIzol® Reagent (Invitrogen) according to the
manufacturer’s protocol and reverse transcribed into cDNA using qScript™ Reagent
(Quanta Biosciences) or iScript™ (Bio-Rad). mRNA levels were measured using
SYBR® Green-based detection (Applied Biosystems) on an ABI 7500 Fast RealTime PCR System (Applied Biosystems). The primers were designed using the NIH
primer design tool. For each gene a dissociation curve was generated and the
results of each sample normalized to the ribosomal protein L32, which serves as
internal control. All measurements were performed in triplicate and expressed as
mean ± standard deviation. Student’s t-test was performed for statistical
significance. Analysis of the microRNA levels was performed following the TaqMan
15

microRNA protocol (Applied Biosystems) and results were normalized to the control
miR-16. All TaqMan probes were purchased from Life Technologies (miR-200a
Assay ID: 000502, miR-200b Assay ID: 001800, miR-200c Assay ID: 000505, miR141 Assay ID: 000463, miR-429 Assay ID: 001077, miR-16 Assay ID: 000391).
Primer sequences are listed in (Table 2).
qPCR primer 5' to 3'
ms L32: F
ms L32: R
ms Zeb1: F
ms Zeb1: R
ms CDH1: F
ms CDH1: R
ms CDH2: F
ms CDH2: R
ms Vim: F
ms Vim: R
ms Crb3: F
ms Crb3: R
ms Itgb1: F
ms Itgb1: R
ms Itgb2: F
ms Itgb2: R
ms Itgb3: F
ms Itgb3: R
ms Itgb4: F
ms Itgb4: R
ms Itgb6: F
ms Itgb6: R
ms Itgb7: F
ms Itgb7: R
ms CSK: F
ms CSK: R
ms Src: F
ms Src: R
ms CRK: F
ms CRK: R
ms CRKL: F

GGAGAAGGTTCAAGGGCCAG
TGCTCCCATAACCGATGTTG
ATGCTCTGAACGCGCAGC
AATCGGCGATCTTTGAGAGCT
CCATCTCAAGCTCGCGGATA
TCCAACGTGGTCACCTGGT
TCCAGAGGGATCAAAGCCTGGGAC
CCGCATCAATGGCAGTGACCGT
TCCAAGCCTGACCTCACTGC
TTCATACTGCTGGCGCACAT
CGGACCCTTTCACAAATAGCA
CGTTGGACTCATCACCTGGG
CTACTTCTGCACGATGTGATGAT
TTGGCTGGCAACCCTTCTTT
CAGGAATGCACCAAGTACAAAGT
CCTGGTCCAGTGAAGTTCAGC
CCACACGAGGCGTGAACTC
CTTCAGGTTACATCGGGGTGA
AGAGCTGTACCGAGTGCATC
TGGTGTCGATCTGGGTGTTCT
GAAAACCCTGTCTCCCGCATA
CGCTGAGAGGCTTATTTTGAAGG
ACCTGAGCTACTCAATGAAGGA
CACCGTTTTGTCCACGAAGG
AAGGTGGAGCACTACCGCATCA
AGAGTCCATCGGCATCTGTGGT
GAGTCACGGACAGAGACTGA
GACATCCACCTTCCTCGTGT
CTAATGCCTACGACAAGACAGCC
TGGGAAGTGACCTCGTTTGCCA
CCTGGACACTACCACCTTAATCG
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ms CRKL: R
ms PINCH1: F
ms PINCH1: R
ms NEDD9: F
ms NEDD9: R
ms ILK: F
ms ILK: R

TCTTCTGCTGTAGGTAAGTTGGG
GGGTTTGTCAAGAATGCTGGCAG
GCACAGTTGAAGTGGTCTGGATG
TCTAAGCAAGGACCAGCCACCA
CTCCTTCTGCTGTCGCTCAAAC
GTGCTGAAGGTTCGTGACTGGA
TCCAGTGTGTGATGAGGGTTGG

hs L32: F
hs L32: R
hs Zeb1: F
hs Zeb1: R
hs Itgb1: F
hs Itgb1: R
hs_CRKL Ori: F
hs_CRKL Ori: R

CCTTGTGAAGCCCAAGATCG
TGCCGGATGAACTTCTTGGT
GGCATACACCTACTCAACTACGG
TGGGCGGTGTAGAATCAGAGTC
GGATTCTCCAGAAGGTGGTTTCG
TGCCACCAAGTTTCCCATCTCC
ATCCACTACCTGGACACCACCA
CCAGGTTATCTTCTGCTGTAGGC

Table 2. Primer sequences used for qPCR analysis

Western Blot Analysis.
Cell lysates were prepared according to the RIPA buffer protocol (CS 9806).
Samples were separated using sodium dodecyl sulfate polyacrylamide gel
electrophoresis and transferred onto Nitrocellulose or polyvinylidene difluoride

(PVDF, for p-CRKL antibody only) membranes. The membranes were blocked using
5 % nonfat dry milk and incubated in primary antibody overnight at 4 °C (see Table 3
for antibody list).
Protein
Cortactin
Crkl
Crkl pY207
Csk
Cttn pY421
Cttn pY421
E-Cadherin

Company
MilliPore
MilliPore
Cell Signaling
BD Pharmingen
Invitrogen
Abcam
BD Pharmingen

Catalog Number
05-180
05-414
3181
610080
44854
47768
610182
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FAK
FAK pY397
FAK pY576/577
FAK pY861
FAK pY925
GFP
Integrin β1
N-cadherin
p130Cas
p130Cas pY410
Paxillin
Paxillin
Paxillin pY118
Src
Src pY416
Src pY418
Src pY527
Vimentin
Zeb1

Invitrogen
Invitrogen
Cell Signaling
Invitrogen
Cell Signaling
Santa Cruz
Cell Signaling
BD Pharmingen
Upstate
Cell Signaling
BD Pharmingen
Abcam
Abcam
Cell Signaling
Cell Signaling
MilliPore
Cell Signaling
Cell Signaling
Santa Cruz

AHO0502
44624G
3281
44-626G
3284
9996
4706
610921
06-500
4011
610620
2264
4833
2108s
2101L
569373
2105
3932S
25388

Table 3. List of antibodies used for Western Blot analysis

3D culture.
Cells were grown in 8-well chamber slides coated with Matrigel (BD 356231)
or Matrigel/Collagen (BD 354249, at the indicated Collagen concentration), as
previously described. [16] The media (RPMI with 10 % FBS and 2 % Matrigel) was
replaced every 2-3 days and the morphology of the cells monitored using a light
microscope. Size of the structures and invasion were scored at the end of the
experiment, with structures being counted invasion-positive if ≥ 1 protrusions were
present. Immunofluorescent staining of the 3D cultures was performed as previously
described [16]. Protein isolation from 3D assays was performed using PBS-EDTA as
previously described [41]. In brief, each well was washed with ice-cold PBS before
adding PBS-EDTA. The Matrigel or Matrigel/Collagen layer was detached from the
glass slide, transferred into a falcon tube and briefly vortex to ensure disruption of
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the layer. The mixture was left on ice for 25 minutes until a pellet formed and
centrifuged at 115 g for 5 minutes. The pellet was washed twice with PBS-EDTA and
spun at 4,000 rpm for 2 minutes before the cells were lysed with RIPA buffer for
30 minutes on ice. The lysate was cleared by centrifugation and protein estimation
performed. For dissolving the Matrigel/Collagen layer, a Collagenase treatment was
performed after the initial wash. Each well was incubated with Collagenase Type I
(1,000 U/ml, Calbiochem #234153) for 30 minutes at 37 °C.
Immunohistochemistry.
All tissues were formalin fixed and paraffin embedded. The paraffin
embedded tissue sections were deparaffinized in xylene twice for 5 minutes at room
temperature followed by hydration of the samples in graded ethanol (twice 100 %,
twice 95 %, 80 %) for 5 minutes each at room temperature. Antigen retrieval was
performed in citrate buffer (DAKO #S1699) for 25 minutes at 95 °C and allowed to
cool for 20 minutes. Endogenous peroxidase activity was blocked by incubating the
slides in 3 % H2O2 diluted in methanol for 5 minutes. Non-specific protein-protein
interactions were blocked using serum-free protein block (DAKO #X0909) for a
minimum of 1 hour at room temperature. The primary antibody p-Src Y418
(MP569373) was added to the slides at a dilution of 1:50 overnight at 4 °C. For the
negative controls, goat serum was added. After washing with TBST, slides were
treated with a secondary biotinylated antibody (1:300, DAKO #0353) for 30 minutes
at room temperature followed by incubation with peroxidase-conjugated streptavidin
(1:100, DAKO #P0397) for 30 minutes. Visualization of the antibody staining was
performed by adding Chromagen substrate diluted in DAB buffer (DAKO #K3468)
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followed by a counterstain in Hematoxylin for 6 minutes and Scott’s Bluing Reagent.
Slides were dehydrated in graded ethanol for one minute each (80 %, 95 %, 100 %)
followed by incubation in xylene twice for 10 minutes each.
Immunofluorescence.
Acid-washed 18 mm coverslips were coated with either 50 μg/ml poly-L-lysine
or fibronectin (10 μg/ml) before 20,000 cells were plated and grown overnight. Cells
were fixed with 4 % paraformaldehyde/PBS for 20 minutes at 37 °C and washed
three times with PBS. Permeabilization was performed using 0.1 % Triton X-100 for
10 minutes at room temperature followed by three PBS washes. The coverslips were
blocked for a minimum of 1 hour at room temperature with 5 % goat serum/PBS
before the primary antibodies were added overnight at 4 °C (Cortactin Millipore 05180, 1:1000; p-Src Y418, Millipore 569373, 1:50; p-FAK Y861 Invitrogen 44626, 1:50;
Paxillin BD610620, 1:100). After three washes with PBS, the coverslips were
incubated with secondary antibodies labelled with Alexa Fluor® 488 or 546 (Life
Technologies) for 2 hours at room temperature. Staining of F-actin was performed
using Alexa Fluor® 546 Phalloidin (Life Technologies). After the secondary antibody
incubation the coverslips were mounted onto microscope slides using a DAPI
containing mounting solution for the nuclear stain.
Luciferase Reporter Assay.
The three prime untranslated regions (3’-UTRs) were amplified by PCR from
genomic DNA and mutants generated using a QuikChange® II XL site-directed
mutagenesis kit (Stratagene), which were further cloned into the hRL vector. One
day before transfection, 3 x 104 cells were seeded in 24 well plates and co20

transfected with 50 ng pGL3 control vector and 500 ng hRL constructs. Pre-miRs
were added at a final concentration of 30 nM (Ambion). After 48 hours Luciferase
activity was measured following the protocol for the Dual-Luciferase® Reporter
Assay (Promega).
Cytosol/Particulate Separation.
The separation of cytosol and particulate was performed using a
cytosol/particulate rapid separation kit purchased from BioVision (#K267-50). The
workflow is depicted in Fig. 1.

Fig. 1 Workflow of cytosol/particulate separation. Using this
separation method the cytosol and particulate fractions do
not come into contact therefore contaminations can be
avoided.
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Chapter 3
Results
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Zeb1 expression induces a functional EMT in epithelial, non-invasive tumor
cells.
Our previous work with metastasis-prone tumor cells from the KP murine
model revealed that miR-200 repression is necessary in a subset of cells at the
tumor periphery for EMT and metastasis [16, 42]. To test whether Zeb1 expression
in tumorigenic, but non-metastatic cells was sufficient to induce a mesenchymal and
invasive phenotype similar to that observed in the metastasis-competent cells, stable
transfectants were generated with constitutive Zeb1 expression. Constitutive Zeb1
expression in the epithelial 393P cells from the KP model produced a dramatic
morphologic change, with cells displaying a spindle-like, fibroblastic shape (Fig. 2A
& B). This change was partially reversed by re-expression of miR-200, as seen in
the lower panel of (Fig. 2A). F-actin staining demonstrated that the mesenchymal,
invasive 344SQ and 393P_ZEB1 cells display cell protrusions, long actin stress
fibers and enhanced cell matrix contact, which were lost upon miR-200 expression
(Fig. 2B). The morphologic change observed with Zeb1 was concordant with an
EMT, as shown by the mRNA and protein levels of epithelial and mesenchymal
markers (Fig. 3A) and decreases in the miR-200 family (Fig. 3B). As a functional
consequence, Transwell migration and invasion were enhanced in the previously
non-invasive 393P cells, and suppressed upon miR-200 re-expression (Fig. 3C).
Similar results were obtained with a doxycycline-inducible system to express miR200a and/or b in the human H157 lung cancer cell line, producing an MET with
morphologic reorganization into tight epithelial clusters (Fig. 4A), suppression of
mesenchymal and re-expression of epithelial protein markers (Fig. 4B), with the
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Fig. 2 Zeb1 expression induces EMT. (A)
Zeb1 expression causes a morphology
change (middle panel) and is reversed
upon re-expression of miR-200 (lower
panel). Cells were stained with Integrin α6
(red), ZO-1 (green) and DAPI. (B) Cells
grown on agarose and stained with
phalloidin (red), DAPI and cortactin
(green, lower panels).
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Fig. 3 Zeb1 expression induces EMT/miR-200 repression in previously
non-invasive cells. (A) Quantitative RT-PCR (left) and Western Blot
(right) analysis of EMT markers in the indicated cell lines. (B) Taqman
RT-PCR for the miR-200 family members in the indicated cell lines. (C)
In vitro migration and invasion assay for the 393P cell line panel.
* p < 0.004, ** p < 0.001
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Fig. 4 Loss of miR-200 in human H157 cells
causes an MET. (A) Induction of miR-200a and
b in H157 causes a morphology change. (B)
Western Blot analysis of EMT markers in H157
+/- miR-200a and/or b. (C) In vitro migration
and invasion assay for the inducible H157 cells.
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most pronounced effect seen upon combined miR-200a and b expression. The
induction of MET in H157 cells upon miR-200 induction significantly suppressed the
migratory and invasive ability of the cells in Transwell assays (Fig. 4C).

miR-200 repression alters cell-cell and cell-matrix interactions.
We utilized a well-established 3D culture assay to study the importance of the
ECM in regulating tumor cell behavior in coordination with Zeb1/miR-200 expression
changes [41]. To model the extracellular matrix composition found in tumors, cells
were grown on a Matrigel matrix or a mixture of different Matrigel/collagen type I
concentrations and then stained for markers to reveal the differential 3D
organization. Control cells grew as rounded, non-invasive colonies in all conditions,
but upon Zeb1 expression displayed a progressively invasive response upon growth
in collagen type I, dependent upon the collagen concentration (Fig. 5A, middle row,
and Fig. 5B). At the highest collagen concentration, ~70% of the colonies were
invasive. Upon re-expression of miR-200 the cells displayed a more organized
epithelial acinar structure in Matrigel culture, with pronounced cortical actin staining,
and suppression of the collagen-induced invasion (Fig. 5A, bottom row). These
results suggest that miR-200 repression enhances the response of the cells to
external stimuli from the ECM, producing a highly invasive phenotype.
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Fig. 5 miR-200 repression primes cells to external stimuli and causes alterations in
cell-cell & cell-matrix interactions. (A) Morphology of spheres grown in a Matrigel
matrix (left two columns) and stained with Integrin α6 (red), ZO-1 (green) and DAPI;
or grown in a mixture of Matrigel and collagen I at the indicated concentrations. (B)
Quantification of the spheres grown in Matrigel (MG) and Matrigel/collagen I at day
7. For each condition 30 structures were measured in size and 75 structures scored
for invasiveness.
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Integrin β1 is necessary for the invasion of murine mesenchymal cell lines.
Integrins are important sensors of the cellular environment, transducing
changes in the surrounding ECM to drive intracellular signaling. Based upon the
altered responsiveness of tumor cells to collagen I in the matrix upon loss of miR200, we screened for changes in the expression or functionality of integrin subunits
induced by EMT. Screening of multiple integrin β subunits revealed that Itgβ1 is
highly expressed in the mesenchymal 393P_ZEB1 cells. Additionally, Itgβ1 was upregulated in the 2D vs. 3D cultures of 344SQ, paralleling the normal changes in miR200 expression upon 3D growth (Fig. 6A). Western Blot analysis of the murine cell
panel showed expression of Itgβ1 in epithelial and mesenchymal cell lines, with only
slightly higher expression in the mesenchymal cells (Fig. 7A). We next investigated
the functional effect of an Itgβ1-blocking antibody on tumor cell invasion in 3D
cultures. The antibody significantly decreased the invasive ability of 393P_ZEB1
cells when grown in Matrigel/collagen I (Fig. 7B), as compared to an Itgβ3-blocking
antibody that produced no effect (Fig. 6B). In addition, combined treatment of Itgβ1
and Itgβ3-blocking antibodies showed a dominant effect of Itgβ1 over Itgβ3, as
addition of α-Itgβ1 at day 4 when cells were beginning to form invasive structures,
still blocked the invasive phenotype. To further confirm the importance of Itgβ1 in
mediating invasion, we used an shRNA-based knockdown approach to deplete
highly invasive 393P_ZEB1 cells of Itgβ1, as confirmed by mRNA and protein levels
(Fig. 8A). Knockdown of Itgβ1 caused a significant reduction in Transwell invasion
for all of the tested shRNAs, blunted migration for three of the four tested shRNAs
(Fig. 8B), and produced a shift to a more epithelial phenotype (Fig. 8C). Strikingly,
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Fig. 6 Integrin β1 is required for mesenchymal cell invasion. (A)
Quantitative RT-PCR analysis of Integrin β subunits in 393P_ZEB1 vs vec
cells (top panel) and in 344SQ grown in 2D vs 3D Matrigel (lower panel)
(B) 393P_ZEB1 cells grown in 1.75 mg/ml Matrigel/collagen I and treated
with an Integrin β3-blocking antibody alone, in combination with an Integrin
β1-blocking antibody (added at the days indicated) or IgG control for 7
days.
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Fig. 7 Integrin β1 inhibition blocks 3D invasion in
murine mesenchymal cell lines. (A) Integrin β1
expression in the murine cell line panel. (B)
393P_ZEB1 cells grown in 1.75 mg/ml
Matrigel/collagen I and treated with an ITGβ1blocking antibody or IgM control for 7 days.
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Fig. 8 Integrin β1 knockdown blocks 2D invasion in murine mesenchymal cell
lines. (A) Quantitative RT-PCR and Western Blot analysis of 393P_ZEB1 cells
after ITGβ1-shRNA knockdown. (B) In vitro migration and invasion assay for the
Itgβ1 shRNA cells. * p < 0.02, ** p < 0.002, *** p ≤ 0.001 (C) Morphology of
393P_ZEB1 cells after Itgβ1 knockdown.
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the Itgβ1 shRNA inhibited 3D invasion in Matrigel/collagen I cultures of 393P_ZEB1
cells to a similar degree as the Itgβ1-blocking antibody (Fig. 9A). We further
depleted the highly metastatic 344SQ cells of Itgβ1, as confirmed by mRNA and
protein levels (Fig. 10A). All of the tested shRNAs showed a significant reduction in
Transwell invasion without any effect on the migration (Fig. 10B), as well as a
morphology change to a more epithelial phenotype in shRNA 5 (Fig. 10C). In order
to see if Itgβ1 knockdown can blunt TGFβ-induced EMT, the shRNA cells were
grown in Matrigel in 3D and treated with TGFβ, which normally causes a hyperproliferative and highly invasive phenotype. Itgβ1 knockdown caused a significant
reduction in the responsiveness to TGFβ, as quantified by sphere size and invasion
(Fig. 10D). In addition, knockdown of Itgβ1 significantly decreased the number of
lung metastases in vivo (Fig. 11). Moreover, widespread metastases were found in
the liver, kidneys, intestines, heart, rib cage and diaphragm of the control mice but
none were observed in the mice who received tumor cells with Itgβ1 knockdown
(Fig. 11).

Integrin β1-collagen I contact is necessary for H157 cell growth and invasion.
To confirm the effect of the Itgβ1-blocking antibody with human cells, we
treated the mesenchymal H157 cells with α-Itgβ1 either from day 0 or day 7, when
the cells were starting to form invasive structures. In both treatment groups, 3D
invasion was significantly inhibited (Fig. 12A), confirming the observations with the
murine cells . shRNA-based knockdown of Itgβ1 produced a partial MET with
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Fig. 9 Integrin β1 shRNA knockdown blocks 3D
invasion in murine mesenchymal cell lines. (A)
393P_ZEB1 Itgβ1 shRNA cells grown in 1.75 mg/ml
Matrigel/collagen I at day 6. For each condition 30
structures were measured in size and 90 structures
scored for invasiveness. Scale bar represents 200
μm.
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Fig. 10 Integrin β1 knockdown blocks 2D invasion and 3D responsiveness to
TGFβ in murine mesenchymal cell lines. (A) Quantitative RT-PCR and Western
Blot analysis of 344SQ cells after ITGβ1-shRNA knockdown. (B) In vitro
migration and invasion assay for the Itgβ1 shRNA cells. * p < 0.015, ** p =
0.0002 (C) Morphology of 344SQ cells after Itgβ1 knockdown. (D) 344SQ Itgβ1
shRNA cells grown in Matrigel at day 11. TGFβ treatment (1 ng/ml) was started
at day 6. For each condition 30 structures were measured in size and 90
structures scored for invasiveness. Scale bar represents 200 μm.
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Fig. 11 Integrin β1 shRNA knockdown reduces metastases in vivo. (A)
Mice injected with 344SQ Itgβ1 shRNA showed a significant reduction in
the number of lung metastases. (B) Control mice showed distant
metastases (e.g. intestines, heart), which were absent in the shRNA
mice.
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Fig. 12 Integrin β1 inhibition blocks 3D invasion
in human mesenchymal cell lines. (A) H157 cells
grown in 1. 5 mg/ml Matrigel/collagen I and
treated with an ITGβ1-blocking antibody from
day 0 or day 7 or IgM control. 90 structures were
scored for invasiveness.
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decreased Zeb1 and N-cadherin levels and

a decreased downstream activation

of the FAK/Src pathway (Fig. 13A & B). This effect was also observed upon miR200ab induction in H157 wild-type cells (Fig. 14B), which also causes a decrease in
the formation of invasive cell protrusions (Fig. 14A). This 3D phenotype was
resembled in the cells treated with the Itgβ1-blocking antibody (Fig. 12A).
Furthermore, the Itgβ1-knockdown cells had a more epithelial morphology (Fig. 14C)
and decreased invasion in Transwell assays (Fig. 15B). In 3D Matrigel/collagen I
cultures the control cells displayed a growth advantage versus the Itgβ1 knockdown
cells and were significantly more invasive. Interestingly, despite normal growth in 2D
culture the shRNA84 Itgβ1 KD cells were unable to survive in 3D culture (Fig. 15A).
This

result

suggests

that

the

Itgβ1-collagen

I

interaction

mediates pro-

growth/survival and pro-invasive signaling.

Invasion of the mesenchymal cells is dependent on FAK/Src pathway
activation.
Given the observed FAK/Src pathway activation, we sought to study the
importance of this pathway downstream of Itgβ1-matrix interactions in our murine
cell line panel. Western Blot analysis showed significant activation of the FAK/Src
pathway (including FAK, Src, paxillin, and cortactin) in the mesenchymal cells
compared to the epithelial cells (Fig. 16A), along with increased phospho and total
CRKL expression. Moreover, in the genetically manipulated 393P cells we observed
an inverse correlation between the activation of this pathway, CRKL expression and
the miR-200 levels (Fig. 16B). Inhibition of FAK with the reversible inhibitor, Y15
38

Fig. 13 Integrin β1 knockdown in human H157 cells. (A)
Quantitative RT-PCR and (B) Western Blot analysis of H157
cells after Itgβ1-shRNA knockdown shows a partial MET.
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Fig. 14 MiR-200 re-expression and Integrin β1 knockdown in H157
cells cause an MET. (A) H157 cells grown in 3D culture
(Matrigel/collagen mixture) for 11 days. (B) Western Blot analysis of
the FAK/Src pathway of H157 cells after induction of miR-200. (C)
H157 Itgβ1 knockdown cells stained for F-actin with Phalloidin and
DAPI for the nucleus. Scale bar is 200 μm.
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Fig. 15 Integrin β1-collagen I contact is necessary for
H157 survival. (A) In vitro migration and assay for the
Itgβ1 shRNA cells. * p < 0.001, ** p < 0.0001 (B) ITGβ1knockdown cells grown on Matrigel/collagen I for 13 days
and analyzed for sphere size and invasiveness. Cells for
sh84 are pseudo colored and not included in graphical
analysis due to phenotype. Scale bar is 200 μm.
* p ≤ 0.0001
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Fig. 16 The FAK/Src pathway is activated
in mesenchymal cell lines. (A) Western
Blot
analysis
shows
increased
FAK/Src/Cortactin pathway activation in
the mesenchymal cells lines of the
murine cell line panel and in cell lines
stably expressing Zeb1 (B).
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(Fig. 17A), significantly decreased 2D migration and invasion (Fig. 17B), and
disassembly of pre-formed invasive cell protrusions in 3D 393P_ZEB1 cultures
within 72 hrs (Fig. 17C). This disassembly was due to decreased cell adhesion as
seen in a cell adhesion assay in which pre-treated cells were grown on different
matrices (Fig. 18A). Cells that received continuous Y15 treatment showed a
decreased ability to adhere, but removal of the inhibitor at the time of plating
revealed that this effect was reversible (rather than a consequence of cell death).
Taken together these results reveal that Itgβ1-mediated invasion is dependent upon
FAK signaling.

Mesenchymal cell invasion is mediated through activated Src signaling.
The tyrosine kinase Src is known to interact with activated FAK, producing
additional FAK phosphorylation at the tyrosine residues Y576/577, Y861 and Y925,
as observed upon ZEB1 expression in the 393P cells (Fig. 19A). To further study the
importance of the FAK/Src pathway in regulating invasion, we assayed the effect of
the Src tyrosine kinase inhibitor, dasatinib. Dasatinib treatment blocked FAK
activation (Fig. 19A) and significantly reduced 2D migration and invasion,
suppressing the highly invasive 393P_ZEB1 cells to the baseline control levels (Fig.
19B). Dasatinib treatment in 3D assays blocked FAK/Src signaling (Fig. 20C), and
inhibited the collagen I-dependent invasion of the mesenchymal 393P_ZEB1 cells
(Fig. 20A & B). Moreover, combination treatment of dasatinib with an Itgβ3-blocking
antibody phenocopied the combined Itgβ3/Itgβ1-blocking antibody treatment
(Fig. 21 A and B). To rule out off targets effects of dasatinib, we used the tyrosine
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Fig. 17 The FAK/Src pathway is activated in mesenchymal cell lines and
required for cell invasion. (A) FAK/Src/Cortactin pathway activation in the
mesenchymal cells lines is inhibited upon a 24 hr treatment with a FAK
inhibitor (Y15). (B) In vitro migration and invasion assay of 393P_ZEB1
cells treated with Y15 (5 μM). (C) FAK inhibition of 393P_ZEB1 cells in
Matrigel/collagen I causes the disassembly of cell protrusions (day 7
pictures). Scale bar is 200 μm.
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Fig. 18 Treatment with the FAK inhibitor affects cell adhesion and is
reversible. (A) 393P_ZEB1 cells pre-treated with the FAK inhibitor Y15
(5μM) for 24 hrs before plated on the different matrices as indicated (FN:
Fibronectin, MG: Matrigel, Coll: collagen type I). Cells were fixed and
stained after 7 hrs post plating.
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Fig. 19 Invasion of the mesenchymal cells is mediated through activated
Src signaling. (A) Western Blot analysis of 393P_ZEB1 and control cells
after dasatinib treatment for 7 hrs. (B) Dasatinib treatment inhibits the
migratory and invasive ability of mesenchymal cells in Transwell assays.
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Fig. 20 3D invasion of the mesenchymal cells is mediated through activated
Src signaling and substrate dependent. (A) 393P_Zeb1 and control cells
grown in 3D cultures. Invasion of 393P_Zeb1 cells in a mixture of
Matrigel/collagen I (1.75 mg/ml) is inhibited upon dasatinib treatment (50
nM). Images were taken at day 7 after a 3 day treatment. (B) Quantification
of sphere size and invasiveness of cells in 3D cultures from (A).
Represented is the average of 3 wells, each measuring 30 structures in size
and scoring 50 structures for invasiveness. (C) Western Blot analysis of cells
grown in 3D from (A) after dasatinib treatment.
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Fig. 21 Dasatinib treatment mimics the Integrin β1
phenotype in 3D assays. (A) 393P_ZEB1 cells grown on
Matrigel/collagen and treated with Itgβ3 blockingantibody alone or in combination with dasatinib or an
Itgβ1 blocking-antibody (combined treatment started day
4). (B) Images and quantification of sphere size and
invasion were taken at day 7. Scale bar is 200 μm. * p <
0.007, ** p = 0.0002, *** p < 0.0001.
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kinase inhibitor Imatinib in 3D studies, which targets the same kinases as dasatinib
except for Src. Imatinib treatment, either started at day 0 or day 4 did not inhibit
invasion (Fig. 22A and B). Dasatinib treatment of human H157 cells blocked Src
pathway activation, suppressing Transwell migration and invasion (Fig. 23A & B),
and causing the cells in 3D culture to remain as single cells or tiny clusters when
added at day 0 (Fig. 23C). Treatment with dasatinib at later time points disrupted the
invasive structures, mimicking the miR-200 phenotype (Fig. 23C bottom row and Fig.
24A). We further investigated the role of the ECM by comparing cells grown in
monolayer culture to cells grown in suspension (Fig. 24B), which showed FAK/Src
pathway deactivation in cells grown in suspension. These results demonstrate that
the FAK/Src pathway activation is driven by the ECM composition and required for
the mesenchymal cell invasion.
In addition to the pharmacological inhibition of Src we utilized a genetic
approach by using either a dominant-active (Y527F, DA) or dominant-negative
(K295R, DN) form of Src. The DA Src was introduced into the epithelial 393P and
412P cells, which showed an increase in activated Src (Fig. 25A) and a slight
morphology change in the 393P cells (Fig. 25B), yet without any functional
phenotype (Fig. 25C). In the 412P cells, the DA Src caused a decrease in migration
(Fig. 25C), opposite to our expectations. The DN form of Src introduced in the
highly invasive 344SQ, 531LN2 and 344LN cells did not inhibit Src activation as
expected by protein levels (Fig. 25D) nor was any morphology change (Fig. 25E)
observed, but rather led to an increase in phospho-Src levels which correlated with
an increase in Transwell migration and invasion (Fig. 25F). Those controversial
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Fig. 22 Invasion of the mesenchymal cells is Src dependent. (A) Invasion of
393P_Zeb1 cells grown in a mixture of Matrigel/collagen I (1.75 mg/ml) is not
inhibited upon treatment with Imatinib (1 μM) compared to dasatinib (50 nM)
treatment. Images were taken at day 7. Scale bar is 200 μm. (B) Sphere size and
invasion represent the average of 3 wells with 30 structures quantified in each.
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Fig. 23 Invasion of the human mesenchymal cells is
mediated through activated Src signaling. (A) Western
Blot analysis of H157 cells treated for 24 hrs with the
dasatinib at 25 and 50 nM. (B) In vitro migration (black
bar) and invasion (grey bar) assay of H157 cells treated
with dasatinib (50 nM). (C) H157 cells grown in
Matrigel/collagen I and treated with dasatinib starting at
day 0 (pictures represent day 9).
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Fig. 24 Dasatinib treatment mimics the Integrin β1 and miR200 phenotype in 3D assays. (A) H157 wild type and
H157_200ab grown in 3D Matrigel/collagen. Dasatinib or
vehicle were added at day 7. Images represent day 11. Scale
bar is 200 μm. (B) Activation of the FAK/Src pathway is
substrate dependent as seen in comparing cells grown on a
petridish vs. suspension cells grown on low adhesion culture
plates for 7 days.
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Fig. 25 Dominant active (Y527F) and dominant negative (K295R) Src. (A) Western
Blot analysis and morphology (B) of 393P and 412P cells infected with DA Src. (C)
Migration of 393P and 412P cells with Csk. (D) Western Blot analysis and
morphology (E) of 344SQ, 531LN2 and 344LN cells infected with DN Src.(F)
Migration and invasion of 531LN2 cells is increased with Csk.
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results could be explained by a possible compensation of other Src- family kinase
(SFK) members. We therefore used another approach to inhibit the SFK members
by infecting the cells with the SFK negative regulator Csk [26]. Infection of the highly
invasive 393P_ZEB1 cells with Csk (with or without a GFP-tag) resulted in an
increase in Csk mRNA and protein levels after induction with Doxycycline (Fig. 26A
and B), yet no decrease in Src activation was observed (Fig. 26B). Alterations in Csk
levels have been shown to affect the cytoskeleton and the ability of cells to adhere to
fibronectin, neither of which showed an effect in the infected cells (Fig. 26C and D)
[43]. Furthermore, growth of the Csk overexpressing cells did not show a phenotype
in a 3D Matrigel/collagen I matrix (Fig. 26E).

Src inhibition blocks TGFβ-induced EMT and in vivo metastasis.
TGFβ is a well-known EMT inducer to which we have previously shown the
metastasis-prone KP cells are quite sensitive [16]. We next asked if Src inhibition
would block the TGFβ-induced EMT in 344SQ or 531LN2 cells. In addition to
dasatinib, the more specific Src inhibitor AZD0530, blocked Src pathway activation
even in combination treatment with TGFβ (Fig. 27A). Interestingly, combined
treatment with AZD0530 showed a decrease of Zeb1, which was reflected in the
cellular morphology. Cells treated with TGFβ alone showed a fibroblastic phenotype,
whereas cells that received TGFβ and AZD0530 displayed an epithelial morphology
(Fig. 27B). Similar to the results with the invasive 393P_ZEB1 cells, treatment with
either Src inhibitor decreased Transwell migration and invasion of the mesenchymal
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Fig. 26 393P_ZEB1 cells infected with Csk. (A) mRNA and (B) protein levels of
393P_ZEB1 cells infected with Csk or GFP-Csk after induction with Dox. (C)
393P_ZEB1 cells infected with Csk grown on gelatin and stained for F-actin and
DAPI. (D) Quantification of adhesion of the infected cells on Fibronectin at the
indicated time points. (E) Csk does not affect invasion of 393P_ZEB1 cells in 3D
Matrigel/collagen I.
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Fig. 27 Migration, invasion & TGFβ response of 344SQ
and 531LN2 cells are blocked with Src inhibitors. (A)
Western Blot analysis of 344SQ and 531LN2 cells treated
with Src inhibitors and TGFβ at the indicated
concentrations for 3 days. (B) Morphology of the 344SQ
cells in the indicated treatment conditions. (C) The
migratory and invasive Transwell assays upon DMSO,
dasatinib (50 nM) or AZD0530 (3 μM) treatment.
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344SQ and 531LN2 cells (Fig. 27C). In 3D culture, treatment of 344SQ cells with
TGFβ caused the spheres to hyper-proliferate and become highly invasive
(Fig. 28A, left column), as reported [16]. Combined treatment with TGFβ and either
of the Src inhibitors led to a significant reduction in sphere size and invasion, which
was more pronounced with AZD0530 (Fig. 28A & B).
The 344SQ cells are paradigmatic of the highly metastatic KP cells in our
syngeneic murine model [16]. To assess whether dasatinib blockade of the Src
signaling pathway could suppress metastases, we injected syngeneic mice with
344SQ cells and dosed them with 10 or 20 mg/kg dasatinib 5 days/week. The results
show that treatment at either concentration significantly reduced the number of lung
metastases (Fig. 29A). Moreover, metastases were found in the liver, kidneys,
spleen, intestines and diaphragm in the control mice but not in the treated mice (Fig.
29B). Immunohistochemical staining of the subcutaneous tumors demonstrated a
strong correlation between p-Src and the number of metastases (Fig. 29C), with the
highest number of metastases found in mice with the highest intratumoral p-Src
levels.

CRKL is a miR-200 target that mediates integrin-dependent signaling.
In order to identify the underlying mechanism of how miR-200 regulates the
Integrin-FAK/Src pathway, we performed a qPCR screen of several integrin
signaling adaptors in our murine cell lines with altered miR-200 expression levels
(Fig. 30A and B). Integrin adaptors have been implicated in many cancer types due
to their importance in transmitting signals from the ECM to intracellular signaling
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Fig. 28 Migration, invasion & TGFβ response of 344SQ
and 531LN2 cells are blocked with Src inhibitors. (A)
Sphere formation of 344SQ in 3D Matrigel cultures.
Images were taken at day 10 and sphere size and
invasiveness scored (B). Dasatinib (50 nM) was added at
day 4, AZD0530 (3 μM) at day 5 and TGFβ (5 ng/ml) at
day 6.
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Fig. 29 Dasatinib treatment in vivo affects metastases and phosphoSrc expression. (A) Primary tumor weight and number of lung
metastases in syngeneic mice treated with dasatinib n=9 (10 mg/kg:
solid shapes, 20 mg/kg: empty shapes) or vehicle n=10. (B) Lung
metastases in the control and treated mice. (C) Distant organ
metastases found in the control mice (DMSO) as indicated by the black
arrows. (D) Immunohistochemistry of subcutaneous tumors from
dasatinib treated or control mice stained for p-Src Y418. The left 2
columns represent mice with a high number of metastases, the right 2
columns mice with few or no metastases.
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Fig. 30 mRNA expression of integrin adaptor
molecules in the murine cell lines. Quantitative
RT-PCR analysis in the 393P_ZEB1 vs. control
cells (A) and 344SQ_200 vs. control cells (B).
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pathways by acting as a central hub [33]. From this screen we identified CRKL,
which inversely correlated with the miR-200 levels. CRKL has been identified as an
oncogene in NSCLC and its overexpression correlates with poor prognosis [36, 38].
As an integrin adaptor molecule it plays an important role as a scaffold protein,
leading to integrin-dependent complex formation especially at sites of focal
adhesions. Its protein expression in the Itgβ1 knockdown cells (Fig. 13B), the murine
cell line panel as stratified by EMT status (Fig. 16A & B) and after treatment with
FAK (Fig. 17A) or Src inhibitors (Fig. 19A) suggested a potential role for CRKL in
coupling the ECM-integrin signals to the FAK/Src pathway.
CRKL is a potential miR-200 target, with two predicted target sites in the 3’
untranslated region (Fig. 31A). To test whether total CRKL levels are regulated by
miR-200, and could therefore regulate signaling downstream of Itgβ1, we
constructed a luciferase reporter containing the CRKL 3’ untranslated region (UTR).
The luciferase reporter assay confirmed that wild-type CRKL is a direct miR-200b
and -c target, with mutation of the second predicted seed sequence or both together
reversing the effect of pre-miR binding (Fig. 31B-D). Functionally, siRNA knockdown
of CRKL reduced in vitro migration and invasion of H157 cells in Transwell assays
(Fig. 32A-C) and 3D Matrigel/collagen I cultures (Fig. 33A). The 3D structures
displayed a more rounded morphology, which was further seen in the adhesion
assay on fibronectin (Fig. 33B). Consistent with its role as an adaptor molecule, the
effect of CRKL was mediated by blockade of FAK and Src localization to focal
adhesion sites (Fig. 34A), rather than phosphorylation of the FAK/Src pathway.
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Fig. 31 CRKL is a direct miR-200 b and c target. (A) Prediction
score of human and mouse CRKL being a miR-200 target using
Targetscan. (B) Luciferase Reporter Assay in H157 cells using
hRL_3’ CRKL wt and mutant constructs. * p < 0.05, ** p < 0.03, ***
p < 0.003 (C) The CRKL 3’UTR contains two predicted miR200b/c/429 sites at the indicated locations. Two point mutations
were introduced in each miR-200 seed sequence (red). (D) Four wt
or mutant 3’UTR constructs were individually generated and cloned
into the hRL vector.
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Fig. 32 CRKL siRNA transfection in H157 cells. (A) CRKL mRNA level
after transfection with CRKL siRNA SMARTpool (final concentration
25 nM) compared to control siRNA and untreated cells. (B) Western
Blot analysis of CRKL siRNA 48 hrs post-transfection using different
siRNA concentrations. (C) Migration (black bar) and invasion (grey
bar) of H157 cells using CRKL siRNA.
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Fig. 33 CRKL siRNA affects 3D invasion and adhesion
on Fibronectin (A) H157 transfected with CRKL siRNA
(or control siRNA) grown in 3D Matrigel/collagen I (1.5
mg/ml) for 9 days. Scale bar is 200 μm. (B) Adhesion
assay of H157 on Fibronectin transfected with CRKL
siRNA.
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Fig. 34 CRKL knock-down affects localization of p-Src and pFAK to focal adhesions. (A) Immunofluorescence staining of
transfected H157 stained for p-Src Y418 or p-FAK Y861. An
average of 30 cells was counted for positive staining at their
focal adhesions (FA). Scale bar is 20 μm.
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In addition to the CRKL siRNA, we used an shRNA-based knockdown
approach in the mesenchymal 344SQ and 393P_ZEB1 cells. CRKL knockdown in
the 344SQ cells (Fig. 35A) caused a significant decrease in the phospho-FAK and
Src levels in shRNA 1 and 2 (Fig. 35B), which affected adhesion on a fibronectin
matrix (Fig. 35C). Furthermore, the knockdown causes a functional decrease in
Transwell migration and invasion (Fig. 36A) and a growth disadvantage in 3D
assays in Matrigel (Fig. 36B). Similar results were obtained in the 393P_ZEB1 cells
with CRKL knockdown (Fig. 37A), even though the effect on the FAK/Src pathway
activation was not seen at the biochemical level (Fig. 37B), the functional
consequences were the same as in the 344SQ cells (Fig. 37C, Fig. 38A and B). The
effect on the localization of phospho-FAK and Src was confirmed biochemically,
using a cytosolic and particulate separation approach. CRKL knockdown causes a
defect in the localization/assembly of the activated FAK/Src complex, as seen by
Western Blot analysis (Fig. 39A). Those results were further validated by
immunofluorescent staining of p-Src and p-FAK, which are no longer localized at the
focal adhesions (Fig. 40A, top 2 panels, and B). In addition, the focal adhesion
marker Paxillin is mostly localized in the cytoplasm in the CRKL knockdown cells
and there is no co-localization found of p-FAK and Paxillin at the focal adhesions
compared to the control cells (Fig. 40A, lower panel, and B). This result confirms that
CRKL is necessary for proper focal adhesion complex formation.
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Fig. 35 CRKL knockdown in 344SQ cells causes a
defect in adhesion. (A) Quantitative RT-PCR and (B)
Western Blot analysis of 344SQ cells after CRKL-shRNA
knockdown. (C) Adhesion of CRKL shRNA cells on
Fibronectin shows a decrease compared to the control
cells (cells stained with DAPI for the nucleus).
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Fig. 36 CRKL knockdown in 344SQ cells causes a decrease in
migration and invasion. (A) CRKL shRNA causes a significant
decrease in Transwell migration and invasion. (B) CRKL knockdown
causes a reduction of growth in 3D Matrigel.
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Fig. 37 CRKL knockdown in 393P_ZEB1 cells causes a defect in
adhesion. (A) Quantitative RT-PCR and (B) Western Blot analysis of
344SQ cells after CRKL-shRNA knockdown. (C) Adhesion of CRKL
shRNA cells on Fibronectin shows a decrease compared to the control
cells.
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Fig. 38 CRKL knockdown in 393P_ZEB1 cells causes a decrease in
migration and invasion. (A) CRKL shRNA causes a significant
decrease in Transwell migration and invasion. (B) CRKL knockdown
has a slight effect on the 3D invasion in Matrigel/collagen I.
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Fig. 39 CRKL knockdown in 344SQ cells causes a
decrease of activated FAK and Src localized at the
membrane. (A) Cytosol and particulate separation
shows a significant decrease in p-FAK, p-Pax, p-Src
and p-Cortactin in the particulate fraction compared to
the control cells. Itgβ1 is the particulate control, β-actin
is the cytosolic control.
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Fig. 40 CRKL knockdown in 344SQ cells affects localization of activated FAK
and Src. (A) Immunofluorescent staining for p-Src Y418 and p-FAK Y861 and costaining for Paxillin (Pax, for focal adhesions) and p-FAK Y861. Scale bar is 20
μm. (B) Quantification of p-Src and p-FAK at the focal adhesions and colocalization of the focal adhesion marker Paxillin with p-FAK. * p < 0.0001
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Chapter 4
Discussion

73

Tumor cell invasion is a complex, multi-step process in which cells acquire a
mesenchymal phenotype through changes in the expression of transcription factors
and actin associated proteins (including metallo proteinases necessary to degrade
the ECM), reorganization of the actin cytoskeleton, as well as changes in the
regulation of microRNAs. [7] The acquisition of the mesenchymal phenotype is
thought to occur through an epithelial-to-mesenchymal transition, a developmental
process which is commonly found in tumor development as well. During the process
of EMT cells are reprogrammed to increase their migratory and invasive abilities
along with decreased cell-cell adhesion allowing for the enhanced motility. The miR200/Zeb1 axis, through its double-negative feedback loop, has been well established
as a master regulator of EMT. EMT is also induced by changes in signaling
pathways (e.g. through mutations) and growth factors such as TGFβ. It is well known
that the expression of miR-200 is able to prevent the TGFβ-induced EMT. [7, 10]
Despite the knowledge of miR-200 being a master regulator of EMT, the mechanism
by how the miR-200/Zeb1 axis regulates the mesenchymal phenotype through
alterations of cellular functions remains unclear and was the focus of this study. We
used murine cell lines derived from the well-established KP model as well as human
lung cancer cell lines to gain a better understanding of the underlying cellular
alterations.
In recent years more focus has been on the tumor ECM instead of just the
tumor cells since cell-intrinsic changes alone have been shown to be insufficient to
drive an invasive phenotype. In our 3D model we confirm those observations by
showing that changes in the miR-200 levels alone cells do not become invasive but
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hyper-proliferative only when grown in a Matrigel matrix. Similarly, previous studies
with our KP model showed that TGFβ-induced EMT or EMT induced by matrix
stiffness is insufficient to produce 3D invasion in a synthetic matrix [44]. This study
shows that the combination of cell-intrinsic changes and the composition of the
ECM, in particular the presence of collagen type I, are necessary to drive tumor cell
invasion. In addition to changes in the expression of several cell-surface proteins
changes during EMT, it has been shown that the ECM undergoes remodeling during
tumor progression [45] . Many of those changes are regulated by microRNAs that
target cell adhesion (e.g. cadherins) and ECM (e.g. collagens, fibronectin) molecules
[46]. Proteomic and mRNA profiling of cell lines derived from our mouse model
showed differences in ECM (collagens, laminins) and adhesion molecules when
comparing non-metastatic to metastatic cells [19], suggesting that miR-200 controls
both cell-intrinsic changes and changes in the ECM. ECM molecules have been
shown to be able to induce an EMT signal, for example through the binding of
collagens to integrins leading to the downstream activation of signaling pathways
increasing cell motility [8]. The presence of collagen I, found in the ECM surrounding
tumors, causes the matrix to become stiffer due to its crosslinking abilities and stiffer
matrices have been associated with increased tumor growth and progression (e.g. in
breast cancer through modulation of microRNAs) [18] [47]. Our finding that β1Integrin-collagen I contact is necessary to drive invasion in 3D cultures supports
those prior findings and further suggests that the balance cell-cell and cell-matrix
interactions driven by miR-200 is crucial for the differential response to the ECM.
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This study shows that Zeb1 drives enhanced matrix responsiveness which is
due to an increase in the FAK/Src pathway activation, which is significantly
decreased in cells with high miR-200 levels. In order to demonstrate the importance
of the ECM in regulating intracellular signaling through β1-Integrin-collagen I contact,
we utilized 2D and 3D in vitro assays in murine and human cells, combined with in
vivo studies in our well-established KP mouse model to show that the modulation of
miR-200 on cell-ECM interactions is applicable in a range of different systems. We
further used pharmacological inhibitors and different knock-down approaches in
vitro, which caused a significant decrease in 2D and 3D invasion, confirming our
hypotheses. Previous work has shown that loss of miR-200 drives in vivo
metastases in our KP model [16], which was significantly decreased upon
pharmacological inhibition of Src or knock-down of Itgβ1 as shown in this study. As
previously mentioned, the interaction of cells with the ECM is largely dependent on
integrins, which further mediate the activation of FAK, yet the exact mechanism of
the FAK pathway activation remains to be elucidated. It is known that FAK is
phosphorylated and re-localizes to integrin-mediated focal adhesions in stiffer
matrices. Once localized at the focal adhesions, it serves as binding partner for Src,
which further activates FAK and it can bind multiple adaptor molecules, including
Paxillin and p130Cas [18]. Similar to previous studies in which FAK or Itgβ1 siRNA
reduced collective cell migration as well as strengthened cell-cell adhesion through
E-cadherin

modulation,

we

showed

here

that

FAK

or

Itgβ1

inhibition,

pharmacologically and by shRNA respectively, caused a significant decrease in cell
migration and invasion [21].
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Due to its important role in EMT, many studies are still trying to understand
how miR-200 suppresses EMT, particularly which cellular mechanisms are being
regulated. Recent studies have identified that the miR-200 family directly targets
multiple actin associated genes, such as moesin, FHOD1, PPM1F, in breast cancer,
therefore inhibiting metastasis. [48, 49] A study published this year by Goodall et al.
[50] shows a genome-wide screen in breast cancer cells of miR-200 targets which
are involved in focal adhesions, invadopodia formation, MMP activity, processes
required for tumor cell invasion and characteristics of actin dynamics. We have
shown that CRKL, as published in this study, is a direct miR-200 b and c target and
functionally effects migration and invasion in lung cancer cells. Our studies have
identified that temporary CRKL inhibition using siRNA is necessary for the outside-in
integrin-dependent FAK/Src activation as seen by a decreased localization of
activated FAK and Src at the focal adhesions. Furthermore, sustained CRKL
inhibition using shRNA affects the FAK/Src activation at the biochemical level,
leading to decreased 2D and 3D invasion and defects in fibronectin adhesion. In
addition, our data suggests that CRKL enhances the inside-out signaling as seen in
the FAK and Src inhibitor studies, suggesting a feedback loop between CRKL and
the FAK/Src pathway (Fig. 41).
This study highlights the importance of the tumor microenvironment,
specifically collagen I, in mediating the activation of intracellular central signaling
pathways that drive tumor cell invasion. We have shown that those central pathways
can be inhibited at multiple levels, making them attractive targets for new combined
treatment strategies in lung cancer patients.
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Further studies are needed to identify the effect of CRKL on the FAK/Src
complex formation at sites of focal adhesions, its downstream effects on actin
reorganization and finally to determine the role of CRKL in in vivo metastases, due
to its clinical relevance in predicting survival outcome.

Fig. 41 Proposed model of miR-200/Zeb1
regulating tumor cell activation through β1integrin-collagen I interaction. Direct targeting
of CRKL by miR-200 disrupts the localization
and activation of the FAK/Src complex at focal
adhesions leading to a decrease in cell
migration and invasion.
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